These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19559572)

  • 21. Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.
    Pinna F; Tusconi M; Bosia M; Cavallaro R; Carpiniello B;
    BMC Psychiatry; 2013 Sep; 13():235. PubMed ID: 24294839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early prediction of antipsychotic nonresponse among patients with schizophrenia.
    Leucht S; Busch R; Kissling W; Kane JM
    J Clin Psychiatry; 2007 Mar; 68(3):352-60. PubMed ID: 17388703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Percentage reduction of depression severity versus absolute severity after initial weeks of treatment to predict final response or remission.
    Lin CH; Chen CC; Wang FC; Lane HY
    Psychiatry Clin Neurosci; 2013 May; 67(4):265-72. PubMed ID: 23683158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Nyhuis AW; Faries DE; Kinon BJ; Baker RW; Shekhar A
    Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.
    Chen YL; Chen KP; Chiu CC; Tai MH; Lung FW
    BMC Psychiatry; 2018 Dec; 18(1):376. PubMed ID: 30509308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
    Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
    J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of suicidal patients with schizophrenia: results from a naturalistic study.
    Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
    Acta Psychiatr Scand; 2010 May; 121(5):359-70. PubMed ID: 19878135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study.
    Schennach-Wolff R; Obermeier M; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Engel RR; Möller HJ; Riedel M
    J Clin Psychopharmacol; 2010 Dec; 30(6):726-31. PubMed ID: 21105273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An early improvement in depressive symptoms predicts symptomatic remission of schizophrenia treated with quetiapine: a multicenter, 4-week case-control study.
    Chou YH; Chiu NM; Yang TT; Feng J; Chan CC; Lee HK;
    Int Clin Psychopharmacol; 2013 Sep; 28(5):255-60. PubMed ID: 23820333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
    Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Huff W; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Möller HJ; Riedel M
    Schizophr Res; 2009 Sep; 113(2-3):210-7. PubMed ID: 19560901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achieving symptomatic remission in out-patients with schizophrenia--a naturalistic study with quetiapine.
    Wobrock T; Köhler J; Klein P; Falkai P
    Acta Psychiatr Scand; 2009 Aug; 120(2):120-8. PubMed ID: 19392812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
    Riedel M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Schennach-Wolff R
    World J Biol Psychiatry; 2012 Jan; 13(1):30-8. PubMed ID: 21568628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
    Lambert M; Holzbach R; Moritz S; Postel N; Krausz M; Naber D
    Int Clin Psychopharmacol; 2003 Sep; 18(5):251-60. PubMed ID: 12920385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.
    Emsley R; Rabinowitz J; Medori R;
    Schizophr Res; 2007 Jan; 89(1-3):129-39. PubMed ID: 17095194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders.
    Schennach-Wolff R; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Jäger M; Möller HJ; Riedel M
    Eur Psychiatry; 2011; 26(5):284-92. PubMed ID: 20435447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai.
    Zhang HX; Shen XL; Zhou H; Yang XM; Wang HF; Jiang KD
    Psychiatry Res; 2014 Jan; 215(1):20-5. PubMed ID: 24230993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.